Actavis Acquiring Warner Chilcott For $8.5 Billion – ValueWalk Premium

Actavis Acquiring Warner Chilcott For $8.5 Billion

Actavis Inc (NYSE:ACT) today announced its definitive agreement to acquire Warner Chilcott plc (NASDAQ:WCRX) in an all stock transaction valued at approximately $8.5 billion.

Actavis, Warner Chilcott Deal:

The generic drug maker Actavis Inc (NYSE:ACT) is to acquire the specialty pharmaceutical company Warner Chilcott.

The deal  means that Warner Chilcott shareholders to receive 0.16  shares of Actavis for each Warner Chilcott plc . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click chat.


X
Saved Articles

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

What’s missing today for many investors is real, straightforward advice.

Especially when it comes to Value Investing and Hedge Funds. 💵

That’s what makes ValueWalk Premium different. Some would say we’re “unusual.”

Our subscribers look forward to clear, easy-to-understand information they can act on.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers

0